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Alarmin S100A8/S100A9 as a biomarker for
molecular imaging of local inﬂammatory activity
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Inﬂammation has a key role in the pathogenesis of various human diseases. The early
detection, localization and monitoring of inﬂammation are crucial for tailoring individual
therapies. However, reliable biomarkers to detect local inﬂammatory activities and to predict
disease outcome are still missing. Alarmins, which are locally released during cellular stress,
are early ampliﬁers of inﬂammation. Here, using optical molecular imaging, we demonstrate
that the alarmin S100A8/S100A9 serves as a sensitive local and systemic marker for the
detection of even sub-clinical disease activity in inﬂammatory and immunological processes
like irritative and allergic contact dermatitis. In a model of collagen-induced arthritis, we use
S100A8/S100A9 imaging to predict the development of disease activity. Furthermore,
S100A8/S100A9 can act as a very early and sensitive biomarker in experimental leishma-
niasis for phagocyte activation linked to an effective Th1-response. In conclusion, the alarmin
S100A8/S100A9 is a valuable and sensitive molecular target for novel imaging approaches to
monitor clinically relevant inﬂammatory disorders on a molecular level.
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I
nﬂammation is the driving force in a vast spectrum of
clinically relevant disorders, among others recognized as a
major pathological mechanism in malignant and degenerative
diseases, infection and autoimmunity. Current imaging markers
mostly reﬂect either metabolism or secondary effects of
inﬂammatory reactions, such as increased perfusion or vessel
permeability, or are only suitable for a very speciﬁc subset of
diseases. In addition, all currently established biomarkers widely
lack a proven prognostic potential. With biomedical research
increasingly discovering the molecular and cellular basis of
diseases and highly speciﬁc molecular therapies at the same time,
both approaches do not provide sufﬁcient diagnostic information.
As a result, individually adapted therapy to manage chronic
inﬂammatory diseases remains widely elusive despite signiﬁcant
therapeutic improvements1.
Numerous imaging approaches have been designed to address
this issue. In vivo visualization of local inﬂammation has
been performed, for example, using F-18-ﬂuorodeoxyglucose
(18F-FDG)-positron emission tomography (PET) or magnetic
resonance imaging (MRI) with or without contrast enhance-
ment2. Although these methods have proven diagnostic value,
their implication in clinical practice has not fostered personalized
therapy, mostly due to a lack of either desirable speciﬁcity (PET)
or sensitivity (MRI).
Targeted imaging approaches to overcome these limitations
would ideally address a biomarker with high expression/release or
accumulation locally at the site of inﬂammation, representative of
early inﬂammatory processes and residual disease activity or a
prediction of ﬂare-ups of disease in remitting-relapsing courses of
chronic inﬂammation. In preclinical animal models, non-invasive
molecular imaging methods would allow for local and long-
itudinal assessment of biomarkers in individual subjects. In the
long-term, such biomarkers would facilitate individual adaptation
of medication and would lead to a signiﬁcant step forward in the
concept of personalized medicine.
In recent years, the concept of alarmins or ‘danger-associated
molecular pattern molecules’ (DAMPs) has emerged as a novel
mechanism for initiating and promoting inﬂammation and has
more recently been recognized as capable of resolving inﬂamma-
tion3–6. Expressed and released during tissue damage or cellular
stress reactions, members of this protein family have been shown
to be early players in the development of inﬂammatory processes.
S100A8 and S100A9, two members of the DAMP-family, are
highly expressed in early inﬁltrating phagocytes. During the
activation of these cells, S100A8/S100A9 complexes are locally
released in virtually all inﬂammatory disorders that are associated
with phagocyte activation, like autoimmune diseases, rheumatoid
arthritis, allergies, cardiovascular diseases, or local and systemic
infections and tumours7, whereas virtually no expression can be
found in healthy tissue. We have previously shown that S100A8
and S100A9 promote inﬂammation via the activation of Toll-like
receptor-4 (refs 8–11). Serum concentrations of S100A8/S100A9
complexes have been shown to be superior over conventional
biomarkers for the monitoring of inﬂammatory disorders,
especially in the detection of residual disease activity and in the
prediction of relapse in arthritis12.
However, biomarkers measured in the blood only reﬂect the
systemic state, which is strongly affected by factors like
metabolism or blood clearance, limiting the speciﬁcity and
sensitivity of these approaches. In contrast to systemic measure-
ments, non-invasive imaging should be able to detect the
expression of alarmins even at the local site of inﬂammation.
Using ﬂuorescence reﬂectance imaging (FRI), we now provide the
ﬁrst evidence that molecular imaging allows for the reliable
detection of S100A8 and S100A9 in preclinical models, locally
expressed during disease, and that visualization of these proteins
in conjunction with further laboratory analysis enables the
monitoring of local inﬂammation with unique sensitivity, even
allowing for the detection of sub-clinical, residual disease activity.
In autoimmune arthritis, we can simultaneously monitor multiple
disease foci by in vivo S100A9 imaging and the extent of disease
could be determined with high precision and even prognostic
value for disease development in independent foci of the same
animal. Moreover, by imaging S100A9 expression, we have
demonstrated the ﬁrst biomarker detecting subclinical differences
in phagocyte activation linked to disease outcome in a model of
Th1/Th2-dichotomy in response to leishmania infection. We
provide evidence that S100A9 may serve as a novel potent
biomarker for monitoring local inﬂammatory processes by
molecular imaging. The broad applicability and consecutive
potential impact on clinical practice is illustrated by assessing the
performance of our integrated approach in exemplary models of
innate and adaptive immunity, autoimmunity and infection, thus
covering representative relevant pathomechanisms of inﬂamma-
tory disorders.
Results
Cy5.5-coupled aS100A9 accumulates at sites of inﬂammation.
To evaluate the feasibility of monitoring S100A9 expression by
optical imaging, we employed irritant contact dermatitis (ICD) as
an inﬂammatory model, exclusively driven by innate immunity,
independent of the adaptive immune system. ICD was induced in
Balb/c mice by the local application of croton oil towards the
ear skin13. 18F-FDG-PET, as a clinically established imaging
technique to assess inﬂammatory activity14, was used to visualize
elevated glucose metabolism in areas of inﬂammation during
ICD. Although inﬂammation can be clearly depicted by the
maximum intensity PET image (Fig. 1a, red arrow), as well as in
the co-registered PET/ computed tomography (CT; Fig. 1b, axial
CT slice), the resulting contrast-to-noise ratio (CNR) is low due
to 18F-FDG being taken up by all glucose-consuming cells
(Fig. 1a).
Figure 1 | In vivo ﬂuorescence reﬂectance imaging of mice during ICD. (a) 18F-FDG-PET image and the fused PET/CT (axial CT slice) (b) of ICD in mice
treated with croton oil on the right ear. The area of inﬂammation (red arrows) can be depicted in the maximum intensity PET image (a, whole body) with
the axial CT slice showing the swelling of the inﬂamed tissue and the local uptake of FDG (ratio inﬂamed ear versus healthy ear¼4.8; b). (c) After the
application of a-S100A9-Cy5.5 to Balb/c mice 24 h after elicitation of ICD, optical imaging (OI) was performed at the time points indicated. Strong
ﬂuorescence intensities were detected only at sites of inﬂammation for up to 96 h. (d) Quantiﬁcation of CNR shows signiﬁcant changes in the affected ears
over the observed time period from 24 to 96 h (baseline¼ time point 0). Data are from three independent experiments (each n¼ 5, mean±s.d., *Po0.05,
**Po0.01, ***Po0.001; P values calculated using Student’s t-test). (e) S100A8/S100A9 serum concentrations 48 h after croton oil application. Data are
from ﬁve mice per group (mean±s.d., ***Po0.001; Student’s t-test). (f) Cryosections of treated and control ears were stained for S100A9-expression. The
ﬁgure shows representative ear sections of an untreated control ear (left) and treated ears with moderately (middle) and strongly (right) elevated
SNR including the corresponding systemic S100A8/S100A9 level. Scale bar, 100 mm. (g) Application of a-S100A9-Cy5.5 or rabIgG-Cy5.5 to WT or
S100A9 / mice 24 h after the elicitation of ICD conﬁrmed the speciﬁcity of optical imaging for S100A9 expression in vivo. Data are from ﬁve mice per
group (mean±s.d., *Po0.05; P-values calculated using one-way analysis of variance with Bonferroni’s post test). a.u., arbitrary units.
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Cy5.5-labelled antibodies against S100A9 (a-S100A9-Cy5.5,
2 nmol of dye/mouse, spectral characteristics: hexc/em¼ 680/
700 nm, band pass¼ 20 nm) were administered intravenously
24 h after croton oil application. Optical imaging was performed
repeatedly 24–96 h after tracer application. Local tracer accumu-
lation, as depicted by FRI, showed the highest level at 24 h
(Fig. 1c,d). Fluorescence signals reﬂecting the high local release of
S100A8/S100A9 correlated well with elevated systemic levels of
Baseline
Total photon counts0 1,200300 600 900
24 72 48 96 h0
OI OI OI OI
Croton
Oil Antibody
Control ICD
S1
00
A8
/A
9 
(ng
 m
l–1
)
0
200
400
600
***
0
20
40
60
80
100
120
140 ***
**
*
*
Time after injection (h)
CN
R 
(a.
u.)
0
20
40
60
80
100
120
140
*
*
CN
R 
(a.
u.)
rabIgGa-S100A9 a-S100A9
S100A9–/–
Local S100A9
SNR
Systemic S100A8/A9
Control ear I Treated I Treated II
12.9 18.5 24.4
747±82
AU
ng ml–1232±42
Wild type mice
–24
967248240
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms5593 ARTICLE
NATURE COMMUNICATIONS | 5:4593 | DOI: 10.1038/ncomms5593 | www.nature.com/naturecommunications 3
& 2014 Macmillan Publishers Limited. All rights reserved.
S100A8/S100A9 complex in the serum of mice 48 h after croton
oil application, as quantiﬁed by ELISA (Fig. 1e, Supplementary
Fig. 1). Local S100A9 expression could be conﬁrmed using
immunohistochemistry (Fig. 1f). In healthy animals, a-S100A9-
Cy5.5 showed a biodistribution that is typical for macromolecular
substances (Supplementary Fig. 2). To discriminate nonspeciﬁc
tracer distribution, rabbit IgG of irrelevant speciﬁcity was labelled
with Cy5.5 (rabIgG-Cy5.5) and injected into a control group of
mice. S100A9-deﬁcient mice (S100A9 / ) served as additional
controls for the speciﬁcity of tracer to target binding. Both sets of
controls showed only a slight increase in ﬂuorescence at local sites
of inﬂammation, most likely reﬂecting hyperemia and Fcg
receptor expression/binding in areas of inﬂammation (Fig. 1g).
The distribution of rabIgG-Cy5.5 and a-S100A9-Cy5.5 in either
healthy wild-type (WT) animals or non-involved organs was
virtually identical (Supplementary Fig. 2).
Monitoring local inﬂammation in allergic contact dermatitis
(ACD). To assess the capability of S100A9 imaging to reﬂect
phagocyte activity in T-cell-dependent adaptive immune reac-
tions, we analysed the expression of S100A9 in a model of ACD13.
Two days after the allergen challenge of sensitized mice,
a-S100A9-Cy5.5 or rabIgG-Cy5.5 was administered and
ﬂuorescence intensities were monitored for up to 48 h after
tracer application. Disease progression was assessed by
monitoring the ear swelling during ACD (Fig. 2a). Already after
3 h, the speciﬁc probe accumulated in the area of inﬂammation,
peaking at 24 h (Fig. 2b). FRI data (Fig. 2b,c) were again in good
accordance with increased S100A8/S100A9 serum levels of
258±116 ngml 1 at day 3 (Po0.01) and of 289±91 ngml 1
at day 4 (Po0.001) compared with control mice
(129±42 ngml 1, ﬁve mice per group (two independent
experiments, mean±s.d)) and clinical symptoms (ear swelling;
Fig. 2a). Similar ﬂuorescence intensities of speciﬁc and
nonspeciﬁc antibodies were obtained in unaffected ears,
representing a perfusion background signal (Fig. 2c). To further
differentiate the accumulation of labelled speciﬁc versus
unspeciﬁc antibody in the region of inﬂammation, 2 nmol of
both Cy5.5-labelled anti-S100A9 and Cy7-labelled rabIgG were
injected simultaneously in vivo during ACD. Fluorescence signals
obtained after the separate excitation of both probes were
acquired and compared with data derived in vitro under
deﬁned conditions. The Cy5.5/Cy7 (reﬂecting a-S100A9/rabIgG)
ratio in vitro was constant (1.83±0.15); however, we observed a
signiﬁcant increase to 4.73±1.31 in vivo (Fig. 2d). To rule out the
effects of the dye properties on probe distribution, a-S100A9-
Cy5.5 and a-S100A9-Cy7 were used simultaneously. An identical
biodistribution of the differently labelled probes could be
observed. Although a direct comparison of absolute signal
intensities was obviated by different emission wavelengths and
different quantum yields, the signal ratios between the affected
and unaffected ear were virtually identical (Fig. 2e). A parallel
injection of a-S100A9-Cy5.5 and rabIgG-Cy5.5 did not result in a
further increase in the local signal compared with the injection of
a-S100A9-Cy5.5 alone. As the S100A9-speciﬁc probe is based on
a polyclonal antibody and thus presumably contains only a
relatively small fraction of antigen-speciﬁc antibodies, these data
conﬁrm the speciﬁcity of our ﬁndings (Supplementary Fig. 3a).
Immunohistochemistry showed a signiﬁcant inﬁltration by
CD11b myeloid cells, Gr-1 granulocytes and F4/80
macrophages as a source of locally released S100A8/S100A9
(Supplementary Fig. 3b).
Monitoring local activity of inﬂammation in arthritis. S100A8
and S100A9 are highly expressed in synovial tissue in rheumatoid
arthritis and serum concentrations have been shown to be reliable
biomarkers reﬂecting local disease activity10,11,15. We performed
optical imaging of S100A8 and S100A9 expression in vivo in a
murine collagen-induced arthritis (CIA) model and correlated
imaging data with the clinical scores of disease activity. CIA was
induced by immunization of DBA/jdba1/j mice with type II
collagen. Clinical manifestations of arthritis started around day 7
after the last collagen injection. Symptoms prevailed for up to
3 weeks to different degrees in the foot joints. Mice received
labelled antibodies 1 week after the last collagen injection
(day 28). Optical imaging was performed starting 24 h after dye
application.
Owing to the highly variable inﬂammatory response of
individual joints in CIA, we performed a clinical scoring for
each individual foot on the basis of a three-point scale (CS0, CS1
and CS2) accounting for redness, swelling and deformation.
S100A9 expression, as depicted by optical imaging, showed
excellent correlation with clinical scoring, clearly discriminating
clinically mild from severe joint inﬂammation (Fig. 3a) with a
high signal-to-noise ratio (SNR) for severely inﬂamed joints
(Fig. 3b). Even single affected small joints could be clearly
identiﬁed (Fig. 3c). The cumulative disease activity score of all
four feet (range 0–8) correlated well with optical imaging data
presented as mean values for all four feet and systemic S100A8/
S100A9 levels of 1,180±360 ngml 1 in mice with mild arthritis
(CS2-3) versus 170±30 ngml 1 in healthy control mice and
2,700±380 ngml 1 in mice with high disease activity (CS4-6;
Fig. 3d,e). To assess unspeciﬁc tracer distribution, we employed
non-targeted Cy5.5-labelled rabIgG and observed only faint tracer
signals, even in strongly inﬂamed joints (Fig. 3a). The
simultaneous injection of Cy7-labelled antibodies against the
S100A8 subunit of the S100A8/S100A9 heterodimer (a-S100A8-
Cy7, 2 nmol dye/mouse, spectral characteristics: hexc/em¼ 755/
780 nm, band pass¼ 20 nm) and a-S100A9-Cy5.5 showed an
almost identical in vivo distribution with equally speciﬁc
accumulation in target areas (Fig. 3f,g). SNR of a-S100A8-Cy7
and a-S100A9-Cy5.5 showed excellent correlation with disease
activity scores of individual feet (Fig. 3h). To further assess a
potential prognostic value of the presented approach, we
conducted the CIA model in C57BL/6 mice. Development of
arthritis and outcome in this mouse strain is highly variable and
unpredictable. Even during early disease, when ﬁrst clinical signs
of CIA could only just be detected, scans allowed for the safe
delineation of areas of S100A9 expression. All four paws were
scored daily and imaging was repeated when manifesting clinical
signs of inﬂammation were present. We also demonstrated an
excellent correlation between early and late imaging (Fig. 3i,j), as
well as between early imaging and the clinical development of
individual paws (Fig. 3k).
Phagocyte activity during Leishmania major infection.
Experimental leishmaniasis is a well-established model for ana-
lysing the Th1/Th2-dependent immune response to infection.
C57BL/6 mice show early activation of phagocytes within the ﬁrst
days after Leishmania major (L. major) inoculation, which results
in an effective Th1-response and the clearance of parasites. In
contrast, Balb/c mice lack the sufﬁcient activation of phagocytes
in the initial phase of infection, ﬁnally resulting in the develop-
ment of a Th2-dominated, ineffective immune response and
subsequent parasite dissemination. The consecutive granuloma
formation is accompanied by an overwhelming yet inefﬁcient
phagocyte activation in the late phase of disease16.
At day 28 after infection, in the late phase of disease, optical
imaging of infected animals was performed, showing signiﬁcantly
higher ﬂuorescence signals in the feet of infected Balb/c mice as
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compared with C57BL/6 mice and untreated control feet (Fig. 4a,
right images). RabIgG-Cy5.5 conﬁrmed the speciﬁcity of S100A9-
labelling (Fig. 4a, left images). We observed an excellent
correlation of optical signals with systemic S100A8/S100A9 levels
(Fig. 4b) and footpad swelling (Fig. 4c) as a clinical sign of
inﬂammation. Moreover, in C57BL/6 mice, even at day 28 after
infection, ﬂuorescence-reﬂected macrophage activity allowed the
grading of residual inﬂammation (Fig. 4d).
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Using S100A9 imaging, even the critical, initial activation of
the phagocyte system in L. major-resistant C57BL/6 mice could
be detected during the very early phase at day four after infection.
Measurements of S100A8/S100A9 expression in sera or local
wash-outs by ELISA conﬁrmed the detected imaging
signals (Fig. 4e). In contrast, the failure of sufﬁcient early
phagocyte activation in Balb/c mice was associated with the
absence of a signiﬁcant increase in S100A9 expression (Fig. 4f).
We could therefore demonstrate that locally expressed S100A9 is
the ﬁrst imaging marker predicting the development of a Th1
immune response, several weeks before the clinical outcome of
infection.
Discussion
Inﬂammatory disorders like autoimmune diseases, allergies
and acute or chronic infections are important challenges in
health care. The continuously growing understanding of the
biological basis of inﬂammation stimulates the development of
targeted therapies, speciﬁcally addressing selected steps in the
process of pathogenesis. This is accompanied by a growing
demand for speciﬁc diagnostic approaches, which are capable not
only of sensitive detection but also of characterization of the
disease stages on a molecular level. Molecular biomarkers
that meet the requirements as set out by current therapeutic
developments—sensitive reﬂection of disease activity changes
under therapy, safe visualization of subclinical disease activity as a
sign of therapy failure and a prediction of the outcome—are still
missing. However, these requirements are a prerequisite for the
adaptation of personalized therapeutic approaches providing
optimal therapy.
Analysing S100A8 and S100A9, two members of the DAMP
family, our study comprises a novel diagnostic approach: DAMPs
or alarmins are widely accepted to represent initial tissue signals
in response to cell stress and tissue damage, thus representing
ideal candidates for the early and sensitive detection of
developing inﬂammation3,5,17. Both proteins are among the
most upregulated genes in numerous inﬂammatory diseases7,15.
S100A8/S100A9 complexes are secreted during the activation of
immigrating phagocytes or released by necrotic cells because of
tissue damage at local sites of inﬂammation, acting as endogenous
triggers of Toll-like receptor-4 and inducing the expression of
pro-inﬂammatory signalling molecules in phagocytes, lympho-
cytes, endothelial and epithelial cells and osteoclasts8,10,18,19.
In this context, S100A8 and S100A9 show typical characteristics
of alarmins or DAMPs. Targeting S100A8/S100A9, we
therefore monitored an inﬂammatory mechanism that has been
shown as highly relevant in different mouse models of
inﬂammation like allergies, autoimmune diseases, arthritis and
infection and has also proven to be a valuable marker for
discrimination and grading of clinically relevant acute and
chronic inﬂammation7–10,13,18,19.
Targeted imaging of cytokines, for example, interleukin-1b or
tumour necrosis factor-a revealed only limited sensitivity and/or
speciﬁcity and a relatively low SNR20–22, probably due to a low
gradient of the cytokine concentration between local
inﬂammatory exudates and systemic serum. In contrast to most
cytokines, chemokines and other pro-inﬂammatory molecules,
the local accumulation of S100A8 and S100A9 is very high (up to
100 mgml 1 and about 50- to 100-fold higher than systemic
concentrations), allowing the sensitive and speciﬁc detection of
local changes in the expression of these molecules15,23. S100A8
and S100A9 comprise about 40% and 5% of the cytosolic proteins
in granulocytes and monocytes, respectively. They are speciﬁcally
released during the interaction of phagocytes with inﬂammatory
activated endothelial cells and can subsequently bind to heparan
sulfate of the endothelial glycocalyx15,24–26. The high abundance
and matrix binding appear to be responsible for the high local
accumulation of these proteins at sites of inﬂammation compared
with other inﬂammatory molecules, which allows the detection of
these molecules even by MRI27 and accounts for the high target to
background ratios that we observed in our in vivo imaging
studies.
In contact dermatitis, as a model of local inﬂammation, we
could demonstrate that the expression of S100A9 is a very
sensitive marker for inﬂammatory processes and reﬂects disease
activity independently of the underlying pathomechanism, for
example, in toxic or in allergen-induced inﬂammation. In
contrast to most imaging studies, we conﬁrmed that our imaging
data closely correlated not only to the local expression of S100
proteins by phagocytes in the dermal inﬁltrate, as determined by
immunohistochemistry, but also to systemic levels of both
proteins and clinical parameters. The speciﬁcity of our data was
conﬁrmed by the use of nonspeciﬁc antibodies (rabbit-derived
IgG without relevant speciﬁcity) to determine perfusion and
unspeciﬁc Fcg-receptor binding. Parallel injection of the S100A9-
speciﬁc probe and rabIgG labelled with different dyes ruled out
in vivo competition for the speciﬁc target or dye-dependent
effects. Moreover, we applied the speciﬁc probe a-S100A9-Cy5.5
in ICD in WT and S100A9 / mice. SNR of a-S100A9-Cy5.5 in
WT mice were signiﬁcantly higher compared with nonspeciﬁc
antibodies, as well as compared with data obtained from
S100A9 / mice. In this model, WT and S100A9 / mice
showed no differences regarding their inﬂammatory phenotype13.
Figure 3 | Detection of single inﬂamed joints in collagen-induced arthritis by optical imaging. (a) CIA was induced in DBA/jdba1/j mice and optical
imaging was recorded by FRI using a-S100A9-Cy5.5 or rabIgG-Cy5.5 at day 28. Individual feet were analysed and compared with clinical scores described
in the Method section (n¼ 5 mice per group, three independent experiments). (b) Comparison of imaging data of a-S100A9-Cy5.5 and rabIgG-Cy5.5 from
mice feet with CS2 conﬁrms the speciﬁcity of our ﬁndings (mean±s.d., *Po0.05, Student’s t-test, n¼ 5 mice per group, three independent experiments).
(c) Enlarged view of only subclinical inﬂammation of single joints. (d) Correlation of imaging data and systemic S100A8/S100A9 levels of mice with clinical
disease severity. Scoring of single feet were added up (maximum score 8 per mouse) and imaging data were calculated as mean values over all four feet.
(e) S100A9 immunostaining of paw sections with CS of 0.5, 1.25 and 2 and control at day 28 conﬁrmed correlation of local S100A8/S100A9 expression
and severity of inﬂammation. Scale bar, 100mm. (f,g) Simultaneous injection of a-S100A8-Cy7 (f) and a-S100A9-Cy5.5 (g) shows an almost identical
distribution pattern in FRI. (h) Upper panel, representative pictures of paws for the different clinical scores. Lower panels, correlation of clinical scores with
SNR for Cy7-labelled anti-S100A8 and Cy5.5-labelled anti-S100A9 (n¼ 5 mice, mean±s.d., *Po0.05, **Po0.01; one-way analysis of variance with
Bonferroni’s post test). (i) CIA was induced in C57BL/6 mice and a-S100A9-Cy5.5-driven FRI was performed at the ﬁrst signs of arthritis (early time point)
and for a second time where disease progression had occurred (late time point, 2 nmol of dye per mouse). All paws were analysed separately and
compared with the clinical scoring as described in (a, n¼6 mice). Representative images of an early (left image) versus late (right image) S100A9 scan are
shown. White arrows indicate inﬂamed areas. Correlation of optical imaging data of early versus late time point (j) and early time point versus late clinical
score (k). To correct for the variable areas of fore- and hind-paws, ﬂuorescence intensities were normalized for the ROI size. Two fore-paws of one mouse
were excluded from the analysis because of an incorrect position in the scanner (j,k). a.u., arbitrary units.
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Analysing CIA, we conﬁrmed an excellent correlation of
S100A9 expression, as detected by optical imaging with local
disease activity in individual joints. In addition, we demonstrated
that the local expression of S100A9 and S100A8 is equally capable
of uncovering sub-clinical disease activity, which is not reﬂected
by established clinical parameters. Using blocking antibodies in
arthritis models in WT and S100A9 / mice revealed that this
alarmin has a pivotal role in the inﬂammatory as well as in the
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destructive process during arthritis10,11,28, indicating that our
imaging approach directly reﬂects major pathogenic aspects of
arthritis.
In CIA, E-selectin-targeted optical imaging has been demon-
strated to reﬂect inﬂammatory activity with similar SNR to our
data29. Interestingly, S100A9 has been shown to induce the
expression of E-selectin in endothelial cells30, indicating that both
methods address different target cells within closely linked
inﬂammatory mechanisms. However, the high local level of
S100A9 at sites of numerous inﬂammatory diseases makes this
molecule more suitable for future imaging approaches in clinical
practice. The detection of leukocyte populations with radio-
labelled antibodies against macrophages (F4/80), T lymphocytes
(CD4, CD3, CD40) or B lymphocytes (CD20), among others, and
cell tracking studies with labelled cells have been used to monitor
inﬂammatory processes in arthritis31,32. However, all of these
approaches suffer from the disadvantage that the inﬁltration of
signiﬁcant numbers of these leukocytes takes a substantial
amount of time and is not the initial event in the inﬂammation
cascade. Moreover, leukocytes may persist during the resolution
of inﬂammation, limiting the diagnostic value of these approaches
for monitoring relapsing remitting courses of inﬂammation.
Therefore, most of these studies have identiﬁed only low SNR and
sometimes entirely failed to show a correlation of imaging results
with disease activity31,32. The tissue destruction associated with
phagocyte inﬁltration is reﬂected by protease activity and can be
detected by small compounds targeting myeloperoxidase,
cathepsin or matrix metalloproteinase activity33–35. However,
these markers, in contrast to S100A8/S100A9, are not sensitive
for the early inﬂammatory reaction, but reﬂect later stages of
disease only.
Yet another interesting ﬁnding in our study was that the
expression of S100A8/S100A9 during the initial phase of an
inﬂammatory (infectious) process was the ﬁrst early and
sensitive marker for subclinical phagocyte activation known to
be linked to the development of an effective Th1-response in this
model. During the very early phase of L. major infection (day 4),
we were able to visualize the effective activation of phagocytes in
resistant C57BL/6 mice. In susceptible Balb/c mice, the lack of
adequate, early phagocyte activation and differentiation into a
pro-inﬂammatory M1-phenotype was reﬂected by low S100
expression in our imaging approach associated with priming a
Th2 response, not sufﬁcient to ﬁght the infection. Hence, the
imaging signal allowed for the prediction of a fatal outcome of
disease, even weeks before full manifestation of the clinical
phenotype and disease dissemination in this particular disease
model.
Our data demonstrate for the ﬁrst time that targeting members
of the alarmin or DAMP family is a potent strategy for functional
molecular imaging of inﬂammatory processes in general and
independent of the underlying pathophysiology. Similar results of
local expression of an alarmin family member could be
demonstrated using a transgene reporter mice model for HSP-
70 expression in ischemic brain injury. However, such transgenic
approaches unfortunately only have limited potential for transla-
tion into clinical applications36. Owing to their speciﬁc mode of
expression and release, S100A8 and S100A9 are sensitive
biomarkers for the immediate response of innate immune
mechanisms to disturbances of tissue homeostasis. The
induction and release of S100A8/S100A9 have been shown to
correlate very well with disease activity in many clinically relevant
disorders, including rheumatoid arthritis, inﬂammatory bowel
disease, autoimmune diseases, infections, allograft rejection or
chronic processes like atherosclerosis, which underlines the
translational potential and high impact of our ﬁndings for
future basic research as well as clinical applications3,7,12. Optical
imaging driven by ﬂuorescently labelled antibodies has a growing
translational potential beyond its impact on preclinical research
and may be applicable for the examination of superﬁcial lesions
such as cutaneous inﬂammation. In addition, ﬂuorescence
endoscopy is gaining increasing interest and could foster the
clinical use of ﬂuorescent contrast agents37; for example, in the
evaluation of inﬂammatory bowel disease, which is known to
exhibit a very high local expression of S100A8/S100A9
(calprotectin)38. The potential of optical imaging of S100A8/
S100A9 for regular clinical use is moreover underlined by the
introduction of an optical scanner for visualization of the disease
activity in rheumatoid arthritis, another inﬂammatory disorder
with high local S100A8/S100A9 expression, currently driven by
ICG ﬂuorescence39. Finally, S100A8/S100A9 are highly
upregulated during tumour development and even in the
developing metastatic niche40. Therefore, another speciﬁc
demand for optical molecular imaging of S100 proteins may
arise in the context of intraoperative imaging for the safe
delineation of malignant tissue during tumour resection41.
For the translation of target-speciﬁc imaging approach into
deep tissue imaging, other label strategies may have to be
explored. Replacing the ﬂuorescent dye with a radionuclide for
either single photon emission computed tomography (SPECT) or
PET imaging would allow for the examination of virtually all
body compartments in humans, with speciﬁcity and sensitivity
resembling that of optical imaging. With hybrid systems like
PET/CT and PET/MRI increasingly applied in clinical imaging,
targeted imaging of S100A8/A9 could be combined with high-
resolution morphology. Targeted contrast agents for MRI, based
on either superparamagnetic iron oxides or Gadolinium, suffer
from the low sensitivity of MRI at clinical ﬁeld strength and—in
comparison to optical or radionuclide-driven imaging—large
Figure 4 | Mouse strain-speciﬁc responses during L. major infection monitored by S100A9 imaging in vivo. (a) Right hind legs of C57BL/6 mice and
Balb/c mice (three independent experiments, each ﬁve mice per group) were infected with L. major, whereas the left hind legs served as controls. FRI was
monitored during the late phase of infection at day 28 after receiving either a-S100A9-Cy5.5 or rabIgG-Cy5.5 (2 nmol of dye per mouse) 24 h earlier.
(b) CNR was calculated for both mouse strains at day 28 after L. major infection. Signiﬁcant strain-speciﬁc differences were found for both local (CNR) and
systemic (S100A8/S100A9) parameters (three independent experiments, each ﬁve mice per group, mean±s.d., *Po0.05, ***Po0.001; Mann–Whitney
U-test). (c) Footpad swelling of infected C57BL/6 mice and Balb/c mice at day 28 and 35 in relation to non-infected contralateral foot pads (mean±s.d.,
n¼ 5 for each mouse strain, ***Po0.001; t-test) demonstrates the different outcome in both mouse strains. (d) Individual comparison of representative
optical imaging data (CNR) of infected C57BL/6 mice at day 28 after infection shows fairly good accordance, suggesting that systemic S100A8/S100A9
levels resemble disease activities. (e) During early L. major infection (day 4), sera (grey bars) and footpad washouts (black bars) of infected and non-
infected mice were collected and analysed for S100A8/S100A9 by ELISA. Systemic and local S100A8/S100A9 levels were already signiﬁcantly increased
in infected C57BL/6 mice as compared with controls. In Balb/c mice, only a minor, nonsigniﬁcant increase in local S100A8/S100A9 expression was
observed. Data are from fvie mice per group (mean±s.d., *Po0.05, **Po0.01, ***Po0.001 and NS, not signiﬁcant; Mann–Whitney U-test). (f) At day 4
already, local upregulation of S100A9 expression could be monitored in resistant C57BL/6 mice by optical imaging (P¼0.047 by t-test) reﬂecting
phagocyte activation. This was not detectable in susceptible Balb/c mice (P¼0.19). Data are from ﬁve mice per group. a.u., arbitrary units.
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amounts of the agent are required to incur a measurable change
in relaxivity42. Although the visualization of tracer accumulation
in areas of inﬂammation could be demonstrated for Gadolinium-
loaded nanoparticles in selected experimental models27, a
convincing approach with translational potential has yet to be
developed. Moreover, the combinatory application of contrast
enhanced MRI and targeted imaging in hybrid systems to acquire
even more diagnostic information in a single examination would
be negated by the use of targeted MRI probes. As a paradigm for
such future developments in molecular imaging, we provide the
ﬁrst fully integrated diagnostic approach on a member of the
DAMP/alarmin family in various preclinical models of different
modes of inﬂammation with clear potential for translation into
clinical practice.
Materials and methods
Mice and reagents. C57BL/6 mice, Balb/c mice (Harlan Laboratories), DBA/
jdba1/j mice (Janvier-Elevage) and S100A9-deﬁcient mice (S100A9 / , back-
crossed to C57BL/6 or Balb/c background (F10 generation))43 were used at the age
of 8–12 weeks, sex matched for each set of experiments and housed under speciﬁc
pathogen-free conditions. All experiments with mice were performed with the
approval of the State Review Board of Nordrhein-Westfalen (Germany) according
to the German law for animal welfare (Permit Number: 84-02.04.2012.A058) or by
the Ethics Committee of University Hospital Nijmegen (Permit Number: DEC
2014-044). All reagents were purchased from Sigma at the highest purity grade
available, unless indicated otherwise.
ELISA. We used an in-house ELISA to determine the concentrations of S100A8/
S100A9 in sera and washouts of footpads, as described earlier (Supplementary
Fig. 1)10. We calibrated our ELISA against puriﬁed S100A8/S100A9 heterodimer as
complexes have been shown to be the predominant form of these proteins.
Antibodies and antibody labelling. Rabbit-derived antibodies addressing S100A9
or S100A8 were puriﬁed via protein G-sepharose and labelled with the ﬂuor-
ochromes Cy5.5 or Cy7 according to the manufacturer’s instructions (GE
Healthcare). Cy5.5-labelled rabbit IgG without relevant speciﬁcity in mice served as
a control. Brieﬂy, 5mg of the antibody was dialysed towards 100mM Na2CO3
buffer, pH 8.0 and a 20-fold excess of the ﬂuorochrome was added for 90min at
RT. The resulting tracer was puriﬁed from unbound dye using size exclusion
chromatography (PD10 column). The labelling efﬁcacy (dye/antibody ratio) was
determined on the basis of ultraviolet-spectra of the puriﬁed dye–antibody com-
pound using PBS as a reference buffer. Typically, the labelling resulted in 2.5–3.0
ﬂuorochrome molecules per antibody, irrespective of the precursors.
In vivo imaging. Mice were held under isoﬂurane inhalation anaesthesia for
the duration of the scan and the imaging chamber was heated to 30. As the total
scan time was usually under 1min, physiological effects due to a signiﬁcant
decrease of body temperature were not to be expected. Mice were intravenously
injected with either the speciﬁc Cy5.5-labelled S100A9 antibody (a-S100A9-Cy5.5,
2 nmol of Cy5.5 B100 mg antibody in total) or Cy5.5-labelled antibody of
irrelevant speciﬁcity (rabIgG-Cy5.5), unless speciﬁed otherwise. In selected
experiments, a-S100A9-Cy5.5- and Cy7-labelled S100A8 antibodies (a-S100A8-
Cy7) or a-S100A9-Cy5.5- and Cy7-labelled S100A9 antibodies (a-S100A9-Cy7)
or a-S100A9-Cy5.5 and rabIgG-Cy5.5 antibodies were administered in parallel
in the same animal for simultaneous detection.
FRI. FRI was performed using the Carestream FX Pro Imaging Station (Carestream
Health). For imaging of Cy5.5-labelled antibodies, excitation light was set to
630 nm using an appropriate bandpass ﬁltre. Emission at 700 nm was recorded
using a ﬁltre-equipped high-sensitivity (4-million-pixel) cooled charge-coupled
device camera. Acquisition time was 30 s for each image, followed by a photo-
graphy-style white light image or conventional X-ray for image fusion and
co-registration of anatomical information.
For the imaging of Cy7-labelled compounds, excitation and emission
wavelengths were 730 and 790 nm, respectively; acquisition time was 30 s.
For the time of examination, mice were held under isoﬂurane inhalation
anaesthesia (2.5% isoﬂurane in air).
For each region of interest measured for imaging analysis, the mean
ﬂuorescence intensity (SI) and resulting standard deviation (s.d.) were determined.
From the acquired ﬂuorescence signals of the target region (SItarget), SNRs were
calculated as SNR¼ SItarget/s.d.background signal.
If possible, the comparison of affected organs (target) and healthy organs
(control) in the same animal CNRs were calculated as CNR¼ (SItarget SIcontrol)/
s.d.background.
PETand CT scanning. Animals were anaesthetized with isoﬂurane, and 10MBq of
18F-FDG in 100ml 0.9% saline was injected intravenously 1 h before each PET
analysis. For PET acquisition, animals were placed on a heat-controlled multi-
modal scanning bed and PET list mode data were acquired for 15min using the
32-module quadHIDAC scanner (Oxford Positron Systems), dedicated to small
animal imaging. The scanner has an effective resolution of 0.7mm (full-width at
half-maximum) in the transaxial and axial directions when using an iterative
resolution recovery reconstruction algorithm. Subsequently, the scanning bed was
transferred to the computed tomography scanner (Inveon, Siemens Medical
Solutions) and a medium resolution (25 mm) CT acquisition was performed for
each mouse. PET data were reconstructed into a single image volume for each
mouse with a voxel size of 0.4 0.4 0.4mm3. CT was reconstructed into a
volume data set with a voxel size of 0.007 0.007 0.007mm3. Image data sets
were co-registered using extrinsic markers attached to the multimodal scanning
bed and commercially available image analysis software (Inveon Research
Workplace, Siemens Medical Solutions).
Immunohistochemistry. Immunohistochemistry of ear sections (cryo) or paw
sections (parafﬁn) was performed as described earlier using puriﬁed rabbit anti-
sera against murine S100A9 (refs 10,13). Brieﬂy, after inhibition of endogenous
peroxidase activity in frozen tissue sections Fc receptors were blocked by
incubating in PBS/1% BSA including 50% normal goat serum (NGS). Slides were
immunostained in a two-step procedure of incubation of primary antibody or
isotype control followed by a horseradish peroxidase-conjugated secondary
antibody using AEC as chromogen. Images were acquired by using an upright
microscope (Axioskop, Zeiss). Paws from arthritis experiments were ﬁxed in 4%
formaldehyde and joints were decalciﬁed with 5% formic acid in PBS during 7
days. After dehydration and embedment in parafﬁn, sections of the paws were cut
(7 mM) in a standardized manner and processed for S100A9 staining. Sections were
treated with 1% H2O2 to inhibit endogenous peroxidase and 0.1% Triton/PBS for
antigen retrieval and additionally incubated with rabbit anti-S100A9 antibodies
followed by a goat-anti-rabbit biotinylated antibody and 3,30 diaminobenzidine
(DAB).
Eliciting irritant and ACD. ICD was induced by the application of 1% croton oil in
olive oil-acetone (1:4) to the dorsal surface of the right ear of mice (n¼ 5 per
group) for 24 h, whereas the left ear served as a control. FRI was performed at 24,
48, 72 and 96 h after tracer application, corresponding to 48, 72, 96 and 120 h after
croton oil treatment, respectively. Subsequently, mice were killed and ears were
snap-frozen in liquid nitrogen and transferred for immunohistochemistry.
To elicit ACD, C57BL/6 or Balb/c mice were sensitized by the application of
25 ml of 0.5% 2,4-dinitroﬂuoro-1-benzene (Sigma) in olive oil/acetone (1:4) to the
shaved abdominal wall on two consecutive days. Six days later, mice were
challenged with 15 ml of 0.4% 2,4-dinitroﬂuoro-1-benzene in olive oil/acetone on
the dorsal surface of the right ear. At day 2, mice were injected with either
a-S100A9-Cy5.5 or rabIgG-Cy5.5 or a combination of a-S100A9-Cy5.5/rabIgG-
Cy7, a-S100A9-Cy5.5/a-S100A9-Cy7 or a-S100A9-Cy5.5/rabIgG-Cy5.5. FRI was
performed at different time points after antibody application, as indicated in Fig. 2.
The disease severity of ACD was monitored by measuring the ear swelling.
Induction and imaging of CIA. Arthritis was induced in DBA/jdba1/j or C57BL/6
mice by immunization using bovine collagen type II as described in detail earlier44.
Brieﬂy, bovine collagen type II (bCII, MD Biosciences) was dissolved in 0.05M
acetic acid at a concentration of 2mgml 1. Mice were injected subcutaneously at
the tail base with 100 mg bCII emulsiﬁed in Complete Freund’s Adjuvant (Difco).
The animals were boosted at day 21 with an intraperitoneal injection of 100 mg
bCII. The onset of polyarthritis occurred around 4–5 days later. Mice were
regularly inspected from day 14 after disease induction and scored for swelling,
erythema and deformation of each joint three times a week (CS0¼ no swelling,
CS1¼ slight swelling and erythema, CS2¼ pronounced oedema including joint
rigidity). Scoring of single joints was added up to a maximum possible score of
eight per mouse (two per paw). Regarding the susceptibility of C57BL/6 mice,
arthritis was evaluated using an extended scoring three-point scale: 0¼ normal;
0.5¼ erythema, light oedema; 1¼mild but deﬁnitely visible, erythema and oedema
of one digit/toe or limb; 2¼ erythema and moderate oedema of at least two digits/
toe or limb; 3¼ erythema, severe oedema of the entire paw and/or rigidity. Imaging
was performed after arthritis was clinically detectable in the majority of treated
animals 24 h after tracer application of either a-S100A9-Cy5.5 or rabIgG-Cy5.5 or a
combination of a-S100A9-Cy5.5/a-S100A8-Cy7. At the end of the experiment,
mice were killed and serum was collected for S100A8/S100A9 quantiﬁcation by
ELISA. Hindpaws were excised and processed for histology.
Experimental leishmaniasis. Cutaneous leishmaniasis was initiated in two dif-
ferent mouse strains (C57BL/6 and Balb/c) by the subcutaneous application of
2 107 promastigotes (stationary phase) of L. major in 50 ml PBS into the right
hind footpad. Footpad thickness of the infected in relation to the healthy foot was
assessed for clinical monitoring of disease. FRI was performed at days 4 and 28
after infection (representative for an early and a late phase immune response), 24 h
after tracer injection. In separate experiments, sera and footpad washouts were
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms5593
10 NATURE COMMUNICATIONS | 5:4593 | DOI: 10.1038/ncomms5593 | www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.
collected at days 4 or 28 after L. major inoculation for S100A8/S100A9 quantiﬁ-
cation by ELISA. Brieﬂy, L. major infected and non-infected hindpaws were
washed out by s.c. injection of 250ml PBS. Without applying any force, in order to
obtain secreted protein, approximately 250 ml of the draining liquid was collected
and used for further analysis.
Statistical analysis. Results are presented throughout as mean values±standard
deviation (s.d.). P-values are given in the ﬁgure legends and values of P40.05 were
considered not to be signiﬁcant. Statistical analyses were performed by parametric
tests (t-test or one-way analysis of variance) and the Mann–Whitney U-test.
References
1. Chan, A. C. & Behrens, T. W. Personalizing medicine for autoimmune and
inﬂammatory diseases. Nat. Immunol. 14, 106–109 (2013).
2. Gotthardt, M., Bleeker-Rovers, C. P., Boerman, O. C. & Oyen, W. J. Imaging of
inﬂammation by PET, conventional scintigraphy, and other imaging
techniques. J. Nucl. Med. 51, 1937–1949 (2010).
3. Chan, J. K. et al. Alarmins: awaiting a clinical response. J. Clin. Invest. 122,
2711–2719 (2012).
4. Harris, H. E., Andersson, U. & Pisetsky, D. S. HMGB1: a multifunctional
alarmin driving autoimmune and inﬂammatory disease. Nat. Rev. Rheumatol 8,
195–202 (2012).
5. Rock, K. L., Latz, E., Ontiveros, F. & Kono, H. The sterile inﬂammatory
response. Annu. Rev. Immunol. 28, 321–342 (2010).
6. Yang, D., de la Rosa, G., Tewary, P. & Oppenheim, J. J. Alarmins link
neutrophils and dendritic cells. Trends Immunol. 30, 531–537 (2009).
7. Ehrchen, J. M., Sunderkotter, C., Foell, D., Vogl, T. & Roth, J. The endogenous
Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate ampliﬁer
of infection, autoimmunity, and cancer. J. Leukoc. Biol. 86, 557–566 (2009).
8. Vogl, T. et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor
4, promoting lethal, endotoxin-induced shock. Nat. Med. 13, 1042–1049
(2007).
9. Loser, K. et al. The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in
the development of autoreactive CD8þ T cells. Nat. Med. 16, 713–717 (2010).
10. van Lent, P. L. et al. Myeloid-related proteins S100A8/S100A9 regulate joint
inﬂammation and cartilage destruction during antigen-induced arthritis. Ann.
Rheum. Dis. 67, 1750–1758 (2008).
11. van Lent, P. L. et al. Active involvement of alarmins S100A8 and S100A9 in the
regulation of synovial activation and joint destruction during mouse and
human osteoarthritis. Arthritis Rheum. 64, 1466–1476 (2012).
12. Foell, D. et al. Methotrexate withdrawal at 6 vs. 12 months in juvenile
idiopathic arthritis in remission: a randomized clinical trial. JAMA 303,
1266–1273 (2010).
13. Petersen, B. et al. The alarmin Mrp8/14 as regulator of the adaptive immune
response during allergic contact dermatitis. EMBO J. 32, 100–111 (2013).
14. Haroon, A., Zumla, A. & Bomanji, J. Role of ﬂuorine 18 ﬂuorodeoxyglucose
positron emission tomography-computed tomography in focal and generalized
infectious and inﬂammatory disorders. Clin. Infect. Dis. 54, 1333–1341
(2012).
15. Frosch, M. et al. Myeloid-related proteins 8 and 14 are speciﬁcally secreted
during interaction of phagocytes and activated endothelium and are useful
markers for monitoring disease activity in pauciarticular-onset juvenile
rheumatoid arthritis. Arthritis Rheum. 43, 628–637 (2000).
16. Sacks, D. & Noben-Trauth, N. The immunology of susceptibility and resistance
to Leishmania major in mice. Nat. Rev. Immunol. 2, 845–858 (2002).
17. McDonald, B. et al. Intravascular danger signals guide neutrophils to sites of
sterile inﬂammation. Science 330, 362–366 (2010).
18. van Zoelen, M. A. et al. Expression and role of myeloid-related protein-14 in
clinical and experimental sepsis. Am. J. Respir. Crit. Care Med. 180, 1098–1106
(2009).
19. Huckins, D. S. et al. A novel biomarker panel to rule out acute appendicitis in
pediatric patients with abdominal pain. Am. J. Emerg. Med. 31, 1368–1375
(2013).
20. Barrera, P. et al. Radiolabelled interleukin-1 receptor antagonist for detection of
synovitis in patients with rheumatoid arthritis. Rheumatology 39, 870–874
(2000).
21. Barrera, P., Oyen, W. J., Boerman, O. C. & van Riel, P. L. Scintigraphic
detection of tumour necrosis factor in patients with rheumatoid arthritis. Ann.
Rheum. Dis. 62, 825–828 (2003).
22. Roimicher, L. et al. (99m)Tc-anti-TNF-alpha scintigraphy in RA: a comparison
pilot study with MRI and clinical examination. Rheumatology (Oxford) 50,
2044–2050 (2011).
23. Achouiti, A. et al. Myeloid-related protein-14 contributes to protective
immunity in gram-negative pneumonia derived sepsis. PLoS Pathog. 8,
e1002987 (2012).
24. Rammes, A. et al. Myeloid-related protein (MRP) 8 and MRP14, calcium-
binding proteins of the S100 family, are secreted by activated monocytes via a
novel, tubulin-dependent pathway. J. Biol. Chem. 272, 9496–9502 (1997).
25. Robinson, M. J., Tessier, P., Poulsom, R. & Hogg, N. The S100 family
heterodimer, MRP-8/14, binds with high afﬁnity to heparin and heparan
sulfate glycosaminoglycans on endothelial cells. J. Biol. Chem. 277, 3658–3665
(2002).
26. Teigelkamp, S. et al. Calcium-dependent complex assembly of the myeloic
differentiation proteins MRP-8 and MRP-14. J. Biol. Chem. 266, 13462–13467
(1991).
27. Maiseyeu, A. et al. In vivo targeting of inﬂammation-associated myeloid-related
protein 8/14 via gadolinium immunonanoparticles. Arterioscler. Thromb. Vasc.
Biol. 32, 962–970 (2012).
28. Cesaro, A. et al. An inﬂammation loop orchestrated by S100A9 and
calprotectin is critical for development of arthritis. PLoS ONE 7, 18 (2012).
29. Gompels, L. L. et al. In vivo ﬂuorescence imaging of E-selectin: quantitative
detection of endothelial activation in a mouse model of arthritis. Arthritis
Rheum. 63, 107–117 (2011).
30. Viemann, D. et al. Myeloid-related proteins 8 and 14 induce a speciﬁc
inﬂammatory response in human microvascular endothelial cells. Blood 105,
2955–2962 (2005).
31. Gaal, J. et al. 99m Tc-HMPAO labelled leukocyte scintigraphy in patients with
rheumatoid arthritis: a comparison with disease activity. Nucl. Med. Commun.
23, 39–46 (2002).
32. Mountz, J. M., Alavi, A. & Mountz, J. D. Emerging optical and nuclear
medicine imaging methods in rheumatoid arthritis. Nat. Rev. Rheumatol. 8,
719–728 (2012).
33. Gross, S. et al. Bioluminescence imaging of myeloperoxidase activity in vivo.
Nat. Med. 15, 455–461 (2009).
34. Ntziachristos, V., Ripoll, J., Wang, L. V. & Weissleder, R. Looking and listening
to light: the evolution of whole-body photonic imaging. Nat. Biotechnol. 23,
313–320 (2005).
35. Peterson, J. D. et al. Optical tomographic imaging discriminates between
disease-modifying anti-rheumatic drug (DMARD) and non-DMARD efﬁcacy
in collagen antibody-induced arthritis. Arthritis Res. Ther. 12, R105 (2010).
36. de la Rosa, X. et al. In vivo imaging of induction of heat-shock protein-70 gene
expression with ﬂuorescence reﬂectance imaging and intravital confocal
microscopy following brain ischaemia in reporter mice. Eur. J. Nucl. Med. Mol.
Imaging 40, 426–438 (2013).
37. Kim, S. Y. & Myung, S. J. Optical molecular imaging for diagnosing intestinal
diseases. Clin. Endosc. 46, 620–626 (2013).
38. Leach, S. T. & Day, A. S. S100 proteins in the pathogenesis and diagnosis of
inﬂammatory bowel disease. Expert Rev. Clin. Immunol. 2, 471–480 (2006).
39. Werner, S. G. et al. Inﬂammation assessment in patients with arthritis using a
novel in vivo ﬂuorescence optical imaging technology. Ann. Rheum. Dis. 71,
504–510 (2012).
40. Hiratsuka, S. et al. The S100A8-serum amyloid A3-TLR4 paracrine cascade
establishes a pre-metastatic phase. Nat. Cell Biol. 10, 1349–1355 (2008).
41. Orosco, R. K., Tsien, R. Y. & Nguyen, Q. T. Fluorescence imaging in surgery.
IEEE Rev. Biomed. Eng. 6, 178–187 (2013).
42. Huang, C. H. & Tsourkas, A. Gd-based macromolecules and nanoparticles as
magnetic resonance contrast agents for molecular imaging. Curr. Top. Med.
Chem. 13, 411–421 (2013).
43. Manitz, M. P. et al. Loss of S100A9 (MRP14) results in reduced interleukin-8-
induced CD11b surface expression, a polarized microﬁlament system, and
diminished responsiveness to chemoattractants in vitro. Mol. Cell Biol. 23,
1034–1043 (2003).
44. Koenders, M. I. et al. Tumor necrosis factor-interleukin-17 interplay induces
S100A8, interleukin-1beta, and matrix metalloproteinases, and drives
irreversible cartilage destruction in murine arthritis: rationale for combination
treatment during arthritis. Arthritis Rheum. 63, 2329–2339 (2011).
Acknowledgements
We thank Eva Nattkemper, Heike Hater, Ina Winkler and Heike Berheide for their
excellent technical support. This work was supported by Grants from the Inter-
disciplinary Center of Clinical Research of the University of Muenster (Vo2/014/09,
PIX), the German Research Foundation (DFG) EI 878 1-1 to M.E., CRC 656 A09, CRC
1009 B8 and B9 from the European Union’s Seventh Framework Program under EC-GA
No. 305266 ‘MIAMI’ to Th.V. and J.R., by the Federal Ministry of Education and
Research (BMBF), project AID-NET to J.R. and CR-UK (C1519/A6906) and the KCL-
UCL Comprehensive Cancer Imaging Centre CR-UK and EPSRC, in association with the
MRC and DoH to M.E.
Author contributions
Th.V. designed and supervised the study and experiments, performed animal studies and
wrote the manuscript. M.E. designed the study and the experiments, performed optical
imaging and wrote the manuscript. T.V., B.P., S.Z., K.R. and P.v.L. performed animal
experiments and analysed the data. S.H. and A.F. performed PET and PET/CT experi-
ments and analysed the data. C.G. and C.B. designed and supervised the optical imaging
experiments and edited the manuscript. M.S. supervised the PET imaging experiments
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms5593 ARTICLE
NATURE COMMUNICATIONS | 5:4593 | DOI: 10.1038/ncomms5593 | www.nature.com/naturecommunications 11
& 2014 Macmillan Publishers Limited. All rights reserved.
and edited the manuscript. J.R. designed the study and experiments and wrote the
manuscript.
Additional information
Supplementary Information accompanies this paper at http://www.nature.com/
naturecommunications
Competing ﬁnancial interests: The authors declare no competing ﬁnancial interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
How to cite this article: Vogl, T. et al. Alarmin S100A8/S100A9 as a biomarker for
molecular imaging of local inﬂammatory activity. Nat. Commun. 5:4593 doi: 10.1038/
ncomms5593 (2014).
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated otherwise
in the credit line; if the material is not included under the Creative Commons license,
users will need to obtain permission from the license holder to reproduce the material.
To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms5593
12 NATURE COMMUNICATIONS | 5:4593 | DOI: 10.1038/ncomms5593 | www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.
